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Abstract
The recently published crystal structure of the D3 dopamine receptor shows a tightly packed
region of aromatic residues on helices 5 and 6 in the space bridging the binding site and what is
thought to be the origin of intracellular helical motion. This highly conserved region also makes
contacts with residues on helix 3, and here we use double mutant cycle analysis and unnatural
amino acid mutagenesis to probe the functional role of several residues in this region of the
closely related D2 dopamine receptor. Of the eight mutant pairs examined, all show significant
functional coupling (Ω > 2), with the largest coupling coefficients observed between residues on
different helices, C3.36/W6.48, T3.37/S5.46 and F5.47/F6.52. Additionally, three aromatic
residues examined, F5.47, Y5.48, and F5.51 show consistent trends upon progressive fluorination
of the aromatic side chain. These trends are indicative of a functionally important electrostatic
interaction with the face of the aromatic residue examined, which is likely attributed to aromatic-
aromatic interactions between residues in this microdomain. We also propose that the previously
determined fluorination trend at W6.48 is likely due to a sulfur-π interaction with the side chain of
C3.36. We conclude that these residues form a tightly packed structural microdomain that
connects helices 3, 5, and 6, thus forming a barrier that prevents dopamine from binding further
toward the intracellular surface. Upon activation, these residues likely do not change their relative
conformation, but rather act to translate agonist binding at the extracellular surface into the large
intracellular movements that characterize receptor activation.
Introduction
G protein-coupled receptors (GPCRs) comprise a large class of integral membrane proteins
activated by a wide range of agonists, including small molecule neurotransmitters, peptides,
and light, leading to initiation of a wide range of downstream signaling cascades. Much
research has been done on this class of molecules to elucidate the nature of receptor
activation, i.e., how such a wide variety of agonists acts on hundreds of different receptors to
induce activation of a small family of G proteins1. The recent publication of multiple GPCR
crystal structures in both the inactive and active-like states complements decades of
structure-function studies, resulting in a wealth of information about the function of these
receptors2–6. However, much remains unknown about the nature of the specific events that
cause large conformational changes in the cytoplasmic region of the receptor, resulting in
activation.
*Corresponding Author: dadougherty@caltech.edu.
The authors declare no competing financial interest.
Supporting Information. Figures S1–S3 and Tables S1 and S2. This material is available free of charge via the Internet at http://
pubs.acs.org.
NIH Public Access
Author Manuscript
J Am Chem Soc. Author manuscript; available in PMC 2013 September 12.
Published in final edited form as:
J Am Chem Soc. 2012 September 12; 134(36): 14890–14896. doi:10.1021/ja304560x.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
The recently published high-resolution crystal structure of the human D3 dopamine receptor
(D3R) offers a detailed snapshot of the receptor locked in an inactive, antagonist bound
conformation4. This crystal structure shows a tightly packed hydrophobic core region of
conserved residues that includes a cluster of six aromatic amino acids on helices 5 and 6.
Aromatic residues are traditionally over-represented at binding sites, and in the aminergic
GPCRs, an important role in agonist binding and/or receptor activation has been proposed
for residues in this microdomain7–9. In another family of ligand-activated receptors, the Cys-
loop (pentameric) family of neurotransmitter-gated ion channels, a cluster of aromatics
defines much of the agonist binding site, usually involving an important cation-π interaction
to a protonated amine of the agonist10–12. In the aminergic GPCRs, the protonated amine
has long been assumed to make a strong ionic interaction with the highly conserved D3.32,
and recent crystal structures confirm this4,13,14. A complementary cation-π interaction to the
cationic portion of agonists is still possible, but in the GPCR crystal structures reported to
date, the aromatic residues in this microdomain do not seem to interact with any cationic
center of agonists or antagonists. Instead, a majority of the aromatic residues in this region
are located away from the binding site and appear to form a network of aromatic-aromatic
interactions.
Aromatic-aromatic interactions are an important class of noncovalent interactions that
participate in ligand-protein interactions, active site tuning, and protein stability15–17. For
example, double mutant cycle analysis of two Tyr residues in the bacterial ribonuclease
barnase demonstrated an important T-shaped aromatic-aromatic interaction that contributed
−1.3 kcal/mol of interaction energy toward protein stability18. Similar interactions that
demonstrate comparable interaction strengths have been observed in other proteins19–21. In
addition to aromatic-aromatic dimers, higher order arrangements (trimers, tetramers, and
larger) of aromatic residues have been observed with high frequency in proteins deposited in
the Protein Data Bank22. This indicates a role for added stability through long-range
interactions that bridge distant regions of the protein.
In addition to aromatic-aromatic interactions, the D3R crystal structure suggests a putative
sulfur-π interaction with one of the aromatic residues in this region, as well as a hydrogen
bond conserved across the family. The sulfur-π interaction has been probed in biological
and model systems, and it has been estimated to contribute between 0.5 and 2 kcal/mol to
binding/stability23, although experimental studies in proteins are limited. Studies of
hydrogen bonding also indicate a contribution of between 0.5–2 kcal/mol to protein stability,
however interaction energy data between two polar uncharged residue side chains are
lacking24,25. It has also been shown that the strength of a hydrogen bond is largely
dependent on the polarity of its environment, with hydrogen bonds in the hydrophobic
interior of proteins up to 1.2 kcal/mol stronger than solvent exposed interactions26.
Given their location and conservation, it seems likely that the residues in this region have
both an important structural and functional role in receptor activation. In the D3R crystal
structure, the residues considered here are located at an important interfacial region between
helices 3, 5, and 6, which likely serves as a connector domain that translates agonist binding
in the extracellular region into intracellular helical motion and receptor activation. This
region also likely forms the intracellular “floor” of the agonist/antagonist binding site and
prevents these molecules from binding “lower” in the receptor, toward the intracellular
space. In the present work we investigate the importance and nature of these noncovalent
interactions using double mutant cycle analysis and unnatural amino acid mutagenesis in the
closely related D2 and D4 dopamine receptors.
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Experimental Procedures
Molecular Biology
The human constructs of the DRD2 long form, DRD4 (Missouri S&T), and M2 receptors
were subcloned into the pGEMhe vector, and GIRK1 and GIRK4 were in the pBSMXT
plasmid. Mutagenesis of the DRD2 and M2 receptors was performed using Stratagene’s
QuikChange protocol, and mutagenesis of the DRD4 was performed using Herculase II
Fusion polymerase (Stratagene) because of the high GC content of the cDNA. For nonsense
suppression experiments, a TAG codon was mutated into the site of interest. The cDNA was
linearized using the appropriate restriction enzyme (SbfI for DRD2, DRD4, and M2 and SalI
for GIRK1 and GIRK4). mRNA was produced from the linearized plasmids by using the T7
mMessage Machine kit (Ambion) for DRD2, DRD4, and M2 and the T3 kit (Ambion) for
GIRK1 and GIRK4.
74mer THG73 tRNA was synthesized from a DNA oligonucleotide template containing two
5′ methoxy (C2′ position) nucleotides to truncate transcription using Ambion’s T7
MEGAshortscript kit27. Amino acids chemically appended to dCA were ligated to the end of
the 74mer tRNA using methods previously described28. Acylation of tRNA was confirmed
using MALDI mass spectrometry using a 3-hydroxypicolinic acid matrix. The NVOC
protecting group on the amino acid was removed through a 5-minute irradiation step using a
1 kW Xenon lamp with WG-335 and UG-11 filters.
Oocyte Preparation and RNA Injection
Stage V–VI Xenopus laevis oocytes were harvested and injected with RNA as previously
described28. For nonsense suppression experiments, 20 ng of receptor mRNA was
coinjected with 10 ng each of GIRK1 and GIRK4 mRNA and an equal volume of
deprotected ~1 μg/μL tRNA solution 48 hours before recording. For conventional
mutagenesis, 1–5 ng of receptor mRNA was coinjected with 10 ng each of GIRK1 and
GIRK4 mRNA 48 hours before recording. For some low expressing mutants, receptor and
GIRK1/4 mRNA and tRNA (if applicable) were injected a second time 24 hours before
recording. Wild type recovery and wild type experiments used half the amount of receptor
mRNA. As a negative control, all nonsense suppression sites were tested with a full length
76mer tRNA lacking an attached amino acid. In all cases, no significant expression was
observed.
Electrophysiology
All oocyte experiments were performed on an OpusXpress 6000A (Axon Instruments) using
two-electrode voltage clamp mode. Recording buffers were ND96 (96 mM NaCl, 2 mM
KCl, 1 mM MgCl2, 5 mM HEPES, 1.8 mM CaCl2, pH 7.5) and high K+ ringer (72 mM
NaCl, 24 mM KCl, 1 mM MgCl2, 5 mM HEPES, 1.8 mM CaCl2, pH7.5). Solution flow
rates were 2 mL/min., drug application flow rates were 2.5 mL/min. for DRD2 and DRD4
and 4 ml/min. for M2. Initial holding potential was −60 mV. Data were sampled at 125 Hz
and filtered at 50 Hz. An ND96 prewash was applied for 10 s followed by high K+ for 50 s
to establish basal current and then application of agonist in high K+ for 25 s. Agonist was
then washed out with high K+ buffer for 45 s and subsequently ND96 for 90 s. Agonist-
induced currents were measured using the basal current as the baseline as described
previously 29. Acetylcholine and dopamine (Sigma-Aldrich) dose solutions were made in
high K+ buffer from 1 M stock solutions. A minimum of 8 agonist doses were applied to
each cell and a minimum of three batches of oocytes were used to give the final data.
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Data Analysis
Data were fit to the Hill equation, Inorm = 1/(1 + (EC50/A)) nH, where Inorm is the
normalized current peak at [agonist] = A, EC50 is the concentration of agonist that elicits a
half-maximum response, and nH is the Hill coefficient. EC50 values were obtained by
averaging the Inorm values for each agonist concentration and fitting those values to the Hill
equation. ΔΔG values were calculated using the equation ΔΔG = −RTlnΩ, where R is the
gas constant, T is the temperature (298 °C), and Ω = [EC50(mut1,2)*EC50(WT)]/
[EC50(mut1)*EC50(mut2)].
Results
Mutation Studies of D2R
As noted above, a microdomain of conserved residues on helices 3, 5, and 6, important for
both agonist binding and receptor activation, has been proposed to exist near the binding site
of dopamine in the D2-like dopamine receptors (D2R, D3R, and D4R). The recently
published crystal structure of D3R shows a tightly packed region of aromatic side chains on
helices 5 and 6, along with a key cysteine and threonine on helix 3 (Figure 1). For the most
part these residues do not directly contact the antagonist eticlopride, but rather they appear
to form a connector domain between the agonist binding site and the intracellular domain of
the receptor. In other GPCR structures, aligning aromatic residues are also not in contact
with bound agonists/antagonists.
Although GPCRs are not ion channels, we are able to measure an electrophysiological
readout of receptor activation through G protein-coupled inward-rectifying K+ (GIRK)
channels. GIRK channels are activated by the binding of Gβγ subunits released from Gαi/o-
coupled GPCRs upon GPCR activation30–32. This assay has been described previously for
the D2 and M2 muscarinic receptors and provides a sensitive readout of Gαi/o-coupled
GPCRs expressed in Xenopus laevis oocytes29.
The assay we use is not applicable to D3R because the receptor has a high binding affinity
for dopamine and thus prevents adequate washing off of agonist between drug
applications33. The residues of interest are however highly conserved across the Gαi/o-
coupled D2-like family with only substitutions of phenylalanine for tyrosine at 5.48 and
cysteine for phenylalanine at 5.51 in the D4R. Guided by the D3R crystal structure, we
evaluated putative pairwise interactions between residues in this microdomain to determine
whether these residues are functionally coupled using double mutant cycle analysis. We
have primarily investigated the closely related D2R, but we have also considered the more
distantly related D4R.
Residues of interest were mutated to alanine to determine whether the receptor would
function in the absence of each side chain (Table 1). Most alanine mutants were able to
activate GIRK1/4 channels upon exposure to viable concentrations of dopamine (< 100
μM), generally with quite substantial shifts in EC50. However, S5.46A, W6.48A, and
F6.51A did not produce sufficient responses to applied dopamine. The more subtle
mutations S5.46C, W6.48F, and W6.48Y did produce functional receptors, with large but
measurable shifts in EC50. F6.51Y did not display a significant shift in EC50 (Supplemental)
and F6.51W did not functionally express, and therefore this site was not examined further.
To evaluate potential functional coupling of these residues, double mutant cycle analysis
was performed using the mutants described in Table 1 (Figure 2, Table 2). Mutant cycle
analysis is a standard technique used to determine whether the perturbing effects of two
single mutants are functionally coupled or act independently. This is done by calculating a
coupling coefficient (Ω = [EC50(mut1,2)*EC50(WT)]/[EC50(mut1)*EC50(mut2)]). If the two
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mutations are independent of each other, Ω ~1. Mutant cycles using EC50 values have been
reported for multiple receptors to signify important protein-ligand and residue side chain
interactions34–38. We appreciate, however, that the EC50 values presented here result from a
complex signaling process, and so care must be taken in interpreting the results. As such, we
have rejected the common practice of converting Ω values to ΔΔG values (=−RTln(Ω)), as
this could be pushing the analysis too far. In the present case, an Ω > 1 indicates that the
double mutant is less functional than predicted from the single mutants, and an Ω < 1
indicates that the double mutant is more functional than predicted. We do not think it is
meaningful to distinguish these two cases, and simply conclude that if Ω deviates from unity
by more than a factor of 2, the residues interact significantly. To facilitate comparisons we
report Ω values < 1 as fractions, such that a mutant pair with an Ω of 1/5 would have the
same interaction strength as a mutant pair with an Ω of 5.
In the D3R crystal structure, the side chain of C3.36 points directly into the face of the
aromatic ring of W6.48. Mutant cycle analysis suggests a functionally important interaction
between the two, with Ω values of 1/14 and 1/10 for the C3.36S/W6.48F and C3.36S/
W6.48Y pairs, respectively (Table 2). C3.36S was used in place of C3.36A due to higher
receptor expression levels of the single and double mutants.
Other strong side chain couplings were observed between F5.47/F6.52 and F5.47/F5.51,
indicating the presence of important aromatic-aromatic interactions in this region. The
strongest interaction was observed between the putative hydrogen bond pair T3.37/S5.46.
We recognize the potential complication of using cysteine mutants to probe this interaction,
in that a disulfide bond could form and this could impact the mutant cycle analysis.
However, the cysteine mutants were the only ones that expressed adequately to allow mutant
cycle analysis. Treatment with DTT was inconclusive, presumably because of the presence
of an important disulfide on the extracellular surface between helix 3 and extracellular loop
2. We are confident however that a hydrogen bond exists between these residues due to the
overlapping electron density of the oxygen atoms of both side chains in the crystal structure.
Both T3.37 and S5.46 were individually sensitive to mutation, and no other double mutant
of T3.37/S5.46 functionally expressed. Weaker coupling energies were observed for the
F5.51/F6.52 and F5.47/Y5.48 pairs, but there is still evidence for a meaningful interaction.
Nonsense suppression experiments
To further examine the nature of the interactions identified through mutant cycle analysis,
unnatural amino acid mutagenesis was performed. Mutation of a residue to an unnatural
analog can produce a more subtle perturbation, avoiding the potential issues that mutating
large bulky aromatic residues to alanine can cause, such as forming destabilizing cavities. In
the past we have used progressive fluorination of aromatic amino acid side chains to
especially good effect. The surface of the aromatic side chains of Phe, Tyr, and Trp contains
a build-up of negative electrostatic potential that leads to significant noncovalent
interactions that are not possible with simple hydrophobic residues such as Leu, Ile, and Val.
Successive fluorination of the aromatic ring diminishes the negative electrostatic potential
and thus weakens noncovalent interactions. The strongest of the noncovalent interactions
involving aromatics is the cation-π interaction, in which a full positive charge is attracted to
the negative electrostatic potential of the ring39,40. Fluorination studies have revealed over
20 cation-π interactions across a wide range of proteins10–12. The negative electrostatic
potential of simple aromatics also gives rise to a number of so-called “polar-π” interactions,
in which the positive end of a bond dipole interacts with the face of the ring41. NH and OH
bonds of amines and alcohols/water can interact significantly with aromatics42. The CH
bonds of aromatics are also polarized (Cδ− ••• Hδ+), and this gives rise to the familiar
aromatic-aromatic interactions, in which the positive periphery of aromatic systems and the
negative center of aromatics interact in either T-shaped or parallel-displaced
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geometries16,17. Progressive fluorination should modulate these polar-π interactions just as
it does a cation-π interaction.
Fluorination of residues F5.47, Y5.48, and F5.51 resulted in a linear fluorination trend upon
incorporation of Phe analogs containing 1, 2, or 3 fluorines (Figure 3 and Table 3). As in
previous studies, Y5.48 was probed with fluorinated Phe analogues, as fluorinating a
tyrosine introduces the complicating feature of modulating the pKa of the OH. The Y5.48F
mutation produced only a slight deviation from wild type (supplemental), and therefore it is
expected that Phe analogs should produce relevant data. These results are indicative of an
electrostatic interaction involving the face of the residue being fluorinated, because
fluorination should only significantly diminish the electrostatic component of interaction.
F5.47Cha was previously reported to exhibit a near-wild type EC5029. This is inconsistent
with the interpretation that the fluorination trend shown here is a result of an electrostatic
interaction with the face of this side chain, as substituting cyclohexylalanine for
phenylalanine should eliminate the electrostatic effect observed at this site. We have found
considerable inconsistency in the expression of the F5.47Cha mutant, such that we have
been unable to reproduce the previously reported results. As such, we conclude that there is
a functionally important electrostatic interaction occurring with the face of F5.47. We have
also previously reported a similar fluorination trend for W6.48 (reproduced here in Figure 3
and Table 3). Previous fluorination studies of F6.51 and F6.52 in the D2R receptor were
inconclusive, in part due to complications from steric effects29.
D4R
Fluorination studies in the D4 receptor produced results similar to what was observed in the
D2R receptor, with the exception of F5.48, where no fluorination trend was observed. This
is surprising, given the homology between the receptors, and the fact that all the aromatic
residues examined except 5.51 (Cys in D4R) are conserved between the two receptors. It is
also interesting to note that C3.36 and W6.48 show no functional coupling in the D4R
receptor (supplemental), despite the observed fluorination trend at W6.48. These data
indicate that although the receptors show considerable sequence conservation, significant
structural/functional differences between the two receptors do exist. This is also supported
by the difference in homology and pharmacology patterns between receptors. D2R and D3R
display higher sequence identity to each other (52%) than either do to D4R (39% and 41%,
respectively)43, and studies show that the pharmacologies of D2R and D3R are more similar
than either are to D4R44. It is therefore likely that the D3R crystal structure provides a less
accurate depiction of the D4R receptor than it does for the D2R receptor.
M2
The M2 muscarinic acetylcholine receptor contains a conserved aromatic residue at
positions 5.47(F), 5.48(Y), 6.48(W), and 6.51(Y). It was previously determined that the M2
receptor did not show evidence of an electrostatic interaction at W6.48 29. In this study we
show that the M2 receptor also does not exhibit an electrostatic interaction at F5.47. This is
not surprising, because the M2 receptor does not have an aromatic residue at the 5.51(V) or
6.52(N) positions, providing no aromatic residues to interact with the face of F5.47. We
have also done a preliminary evaluation of several other residues that contribute to the
aromatic cage of the M2 receptor (Y6.51, Y7.39, and Y7.43), but we have found these
residues to be very sensitive to even subtle mutations such as Tyr-to-Phe, and so we have
been unable to evaluate them in ways that parallel the work described here.
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Discussion
It has long been appreciated that there are a number of conserved aromatic amino acids in
class A GPCRs, and many studies have proposed that these residues play a crucial role in
binding agonists/antagonists. We have previously probed some of these aromatics in the
D2R and produced evidence that one highly conserved residue, W6.48, makes a direct
binding interaction to dopamine. Our model also proposed a rotation of the side chain of
W6.48 to facilitate dopamine binding, and indeed this residue has long been proposed to
play the role of a “rotamer toggle switch” in GPCR activation. However, as more and more
GPCR crystal structures with agonists/antagonists bound have appeared, a pattern has
emerged in which drugs bind relatively “high up” (toward the extracellular space) in the
receptor, at a location where many of the residues of this aromatic microdomain cannot
directly contact the drug. Certainly in the D3R structure, which serves as the foundation for
the present study, W6.48 and other contributors to the aromatic microdomain do not directly
contact the bound antagonist eticlopride, and the side chain of W6.48 has not rotated. Many
other structures of GPCRs show a similar conformation for the aligning residue, although in
the recent structures of opioid receptors W6.48 does contact bound drug. Also, in a recent
structure of the M2 receptor with the antagonist QNB bound, the drug is bound more deeply
in the receptor crevice, where 5 aromatic amino acids form an “aromatic cage” around the
cationic end of the drug, as has been seen in a number of ACh binding sites. However,
W6.48 is the only residue of the aromatic microdomain considered here that contributes to
the aromatic cage. It is interesting, however, that in order to form the aromatic cage of the
M2 receptor, the side chain of W6.48 has rotated to a position not seen in most other GPCR
crystal structures, but that is similar to what we had previously proposed for D2R.
Returning to the D3 structure, a cluster of aromatic residues is evident, but it is unclear what
its functional role might be. The present work was undertaken with a goal of evaluating the
functional significance of this microdomain in the dopamine receptor, with an emphasis on
evaluating possible functional interactions that are implied by the structure. As noted above,
our assay system is not compatible with the D3R, and so we have investigated the closely
related D2R, while also performing more limited studies on the more distantly related D4R
and M2 receptor.
Residue coupling through mutant cycle analysis
We considered various pairwise interactions involving residues C3.36, T3.37, S5.46, F5.47,
Y5.48, F5.51, W6.48, and F6.52 (Figure 2). Of the eight pairs considered, six produced
clearly meaningful interactions (Ω ≥ 4.5), while two others were smaller, but still significant
(Ω > 2). Especially large coupling coefficients are seen with T3.37C/S5.46C, C3.36S/
W6.48F, and F5.47A/F6.52A, providing evidence for strong functional coupling between
residues that directly connect helices 3, 5, and 6. The notion that this cluster of residues
functions as a unit is supported by the long-range coupling seen between F5.51/F6.52 and
C3.36/F5.47.
Probing aromatic-aromatic interactions using unnatural amino acid mutagenesis
While mutant cycle analysis and fluorination of aromatic residues have been previously used
to examine aromatic-aromatic interactions in proteins 45,46, to our knowledge this is the first
example of using unnatural amino acid mutagenesis to examine the electrostatic component
of these interactions. We have successfully incorporated fluorinated phenylalanine and
tryptophan derivatives at a number of conserved residues in this aromatic microdomain of
the D2 dopamine receptor.
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We noted above the previously reported strong and consistent response of W6.48 to
fluorination and our earlier interpretation of this as indicating a cation-π interaction.
However, this interpretation was called into question by the D3R structure. In that structure,
W6.48 is not in a position to contact the amine of drugs or other atoms that may bear a large
partial positive charge, but rather experiences a van der Waals contact with the side chain of
C3.36, in which the sulfur of the cysteine points directly into the face of the Trp side chain.
Mutant cycle analysis establishes a strong coupling between W6.48 and C3.36, indicating
that this interaction is functionally significant. In the D3R crystal structure W6.48 does
make a weak hydrophobic contact with the bound drug eticlopride, and so we cannot
completely rule out a direct interaction between dopamine and W6.48 in the activated
receptor. However, it would be difficult to see how such an interaction could produce the
linear fluorination trend of Figure 3, and so we feel that an interaction between W6.48 and
C3.36 is the more plausible interpretation.
Sulfur-arene interactions are in fact quite common in protein crystal structures. For example,
Met is as likely as Phe or Trp to be near another Trp, with the majority of the interactions
being to the face of the ring47,48. While the nature of the interaction is primarily dispersive,
there is generally considered to be a significant electrostatic component as well49.
We propose that the fluorination of W6.48 is probing this sulfur-arene interaction, and
removing electron density from the aromatic diminishes the magnitude of the interaction. In
addition to a lack of hydrogen atom resolution in the crystal structure, computational studies
disagree whether the face of aromatic side chains preferentially interact with the lone pairs
of the sulfur atom or through an SH-π interaction47,49,50. Our fluorination experiments are
unable to distinguish between the two scenarios because both occur through an electrostatic
interaction with the face of W6.48. Progressive fluorination may also impact the dispersion
component of the interaction, as F is the least polarizable of the elements. The fact that
fluorination of W6.48 in the M2 receptor does not produce a comparable trend is consistent
with this analysis, as residue 3.36 is valine in the M2 receptor, and so no sulfur-arene
interaction is possible. To our knowledge, this is the first example of evaluating a sulfur-
arene interaction by modulating the electrostatic surface of the arene. Note that the
magnitude of the sulfur-arene interaction appears to be considerable. Tetrafluorination of
W6.48 (which essentially makes the aromatic surface electrostatically neutral) results in a
300-fold shift in EC50.
We also see linear fluorination plots for residues F5.47, Y5.48, and F5.51, indicating
noncovalent electrostatic interactions with the faces of these residues. Given the
crystallographic results, we propose that fluorination is probing various arene-arene
interactions in the D2 receptor. We emphasize that our assay is a functional one, indicating
that the noncovalent interactions involving these residues play a significant functional role.
In the past we have considered the relative slopes of such fluorination plots to be indicative
of the magnitude of the electrostatic component of the relevant noncovalent interaction.
Here, the relative values of the slopes are F5.47 > W6.48 > Y5.48 > F5.51. These would
appear to be consistent with expectations from the D3R crystal structure. F5.47 is at the
heart of the aromatic region of this microdomain, and it makes a parallel stacking interaction
with F6.52 and F5.51 and a T-shaped interaction with Y5.48. Y5.48 only makes the single
interaction to F5.47. F5.51 is further away from the other aromatics, and the slope associated
with it is the smallest we have seen for a fluorination plot. We propose that it makes a weak
parallel stacking interaction with F5.47. In our mutant cycle analyses, we paired F5.47 with
both Y5.48 and F5.51, and the latter produced a larger coupling energy than the former,
opposite to the fluorination trend. We are inclined to accept the conclusion from fluorination
that the Y5.48•••F5.47 interaction is stronger than the F5.51•••F5.47 interaction, because of
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the much more subtle perturbation introduced by fluorination vs. the highly perturbing
arene-to-alanine mutation.
The major interactions probed here, involving residues on helices 3, 5 and 6 suggest a
network of interactions that form a belt in the center of the receptor (C3.36/W6.48, F5.47/
F6.52, and T3.37/S5.46). This belt is located between the binding site and what is though to
be the origin of intracellular helical motion. The relative orientations of these residues as
well as residues in the binding site do not change much between the active and inactive
structures in the homologous β2 adrenergic receptor. However, a large movement of the side
chain of F6.44 past I3.40 as well as the appearance of a large bulge at P5.50 are observed,
all of which are located one helix turn toward the intracellular side of this proposed belt
region 3. We therefore propose that the residues examined play an important structural role
in the activation process, specifically serving as a rigid structural unit that prevents
dopamine from binding further toward the intracellular surface and translates agonist
binding into the large intracellular helical movement of helices 5 and 6 that occur upon
agonist binding.
Conservation in Other Receptors
While the residues in the transmembrane domain of GPCRs are highly conserved, it seems
that the functional significance of many residues varies from receptor to receptor. Even
within the same receptor family, such as D2R vs. D4R, aligning residues studied here do not
always respond to functional probes in the same way. This is even more true for the less
closely related M2 receptor. It appears that considerable caution is in order when making
predictions about a GPCR based on structural or functional data from even a close relative
of the receptor.
Conclusions
Using the D3R crystal structure as a model, we identified a conserved domain located
between the agonist binding site and what is thought to be the origin of intracellular helical
motion. Residues in this microdomain in the related D2R were examined using mutant cycle
analysis and unnatural amino acid mutagenesis to determine whether putative interactions
between residues side chains were functionally important. In this study, we demonstrate 7
functionally important noncovalent interactions between residues on helices 3, 5, and 6.
These interactions include aromatic-aromatic, sulfur-π, hydrogen bond, and long range
interactions, which support the notion that this microdomain functions as a unit. We also
show that the largest coupling coefficients are observed between residues on different
helices, indicating an important region of helix connectivity.
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Figure 1.
Space filling model of residues in the aromatic microdomain of the D3R (PDB 3PBL).
Shown are both a side view (A) to position the domain of interest with respect to the
receptor as a whole, and a top-down view (B). Protein residues are shown as space-filling,
while the bound antagonist eticlopride is shown as a stick figure. (C) Enlarged view
showing the residues considered here. Residues are color-coded according to their respective
helices. Eticlopride and the highly conserved D3.32 are shown for reference.
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Figure 2.
Mutant cycle analysis of the residues examined in this study. The strongest coupling values
are observed between residues on different helices. The Ω values between residues are
indicated.
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Figure 3.
Fluorination trends of aromatic residues found in the aromatic microdomain of the D2R. A
linear trend indicates the existence of an electrostatic interaction with the face of the residue
examined.
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Table 1
Conventional mutagenesis of residues in the aromatic microdomain of D2R
Mutant EC50 (μM) Hill n
WT 0.020 +/− 0.001 1.2 +/− 0.1 15
C3.36A 0.49 +/− 0.03 1.1 +/− 0.1 16
T3.37A 1.9 +/− 0.2 1.0 +/− 0.1 13
S5.46A No Response
F5.47A 1.6 +/− 0.2 0.9 +/− 0.1 14
Y5.48A 0.50 +/− 0.02 1.1 +/− 0.1 17
F5.51A 0.47 +/− 0.02 1.1 +/− 0.1 11
W6.48A No Response
F6.51A > 100 10
F6.52A 0.071 +/− 0.003 1.4 +/− 0.1 19
C3.36S 0.67 +/− 0.04 1.1 +/− 0.1 17
T3.37C 2.1 +/− 0.1 1.1 +/− 0.1 13
T3.37V No Response
S5.46C 2.4 +/− 0.1 1.0 +/− 0.1 14
W6.48F 3.4 +/− 0.1 1.0 +/− 0.1 16
W6.48Y 0.65 +/− 0.04 1.0 +/− 0.1 17
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Table 2
Mutant cycle analysis of putative pairwise interactions in the D2R
Mutant EC50 (μM) Hill n Ω
T3.37C/S5.46C 2.0 +/− 0.1 1.0 +/− 0.1 17 1/125
F5.47A/F6.52A 125 +/− 9 1.3 +/− 0.1 18 23
C3.36S/W6.48F 8.1 +/− 0.4 1.0 +/− 0.1 18 1/14
C3.36S/W6.4 Y 2.1 +/− 5.7 1.0 +/− 0.1 15 1/10
F5.47A/F5.51A 5.7 +/− 0.2 1.0 +/− 0.1 11 1/6.6
C3.36S/F5.47A 12 +/− 1 1.2 +/− 0.1 14 1/4.5
F5.51A/F6.52A 4.6 +/− 0.1 1.1 +/− 0.1 16 2.8
F5.47A/Y5.48 18 +/− 1 1.2 +/− 0.1 12 1/2.2
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Table 3
Unnatural amino acid mutagenesis of aromatic residues in the D2R
Mutant EC50 (μM)
F5.47
Phe 0.026 +/− 0.001
F1Phe 0.087 +/− 0.006
F2Phe 1.0 +/− 0.1
F3Phe 1.3 +/− 0.1
Me2Phe 0.35 +/− 0.02
Y5.48
Phe 0.085 +/− 0.004
F1Phe 0.16 +/− 0.01
F2Phe 0.52 +/− 0.06
F3Phe 1.2 +/− 0.1
F5.51
Phe 0.024 +/− 0.001
F1Phe 0.045 +/− 0.003
F2Phe 0.059 +/− 0.003
F3Phe 0.087 +/− 0.003
W6.48
Trp 0.042 +/− 0.004
F1Trp 0.12 +/− 0.01
F2Trp 0.29 +/− 0.03
F3Trp 0.84 +/− 0.06
F4Trp 1.8 +/− 0.3
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Table 4
Unnatural amino acid mutagenesis of related aminergic receptors
Mutant EC50 (μM)
D4R
F5.47
Phe 0.017 +/− 0.002
F1Phe 0.041 +/− 0.005
F2Phe 0.27 +/− 0.01
F3Phe 0.72 +/− 0.04
Cha 0.55 +/− 0.04
MePhe 0.031 +/− 0.003
Me2Phe 0.10 +/− 0.01
F5.48
Phe 0.018 +/− 0.001
F1Phe 0.019 +/− 0.001
F2Phe 0.025 +/− 0.002
F3Phe 0.030 +/− 0.002
Cha 0.029 +/− 0.002
W6.48
Trp 0.018 +/− 0.001
F1Trp 0.0080 +/− 0.0006
F2Trp 0.026 +/− 0.001
F3Trp 0.070 +/− 0.010
F4Trp 0.13 +/− 0.01
Nap 0.024 +/− 0.002
MeTrp 0.0078 +/− 0.0015
F6.51
Phe 0.018+/− 0.001
BrPhe 0.093 +/− 0.006
CNPhe 0.16 +/− 0.01
F1Phe 0.025 +/− 0.002
F2Phe 0.32 +/− 0.01
F3Phe 0.36 +/− 0.02
Cha 0.39 +/− 0.04
Me2Phe 55 +/− 7
F6.52
Phe 0.019 +/− 0.001
BrPhe 0.039 +/− 0.003
CNPhe 0.025 +/− 0.002
F1Phe 0.0072 +/− 0.0004
F2Phe 6.0 +/− 0.3
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Mutant EC50 (μM)
F3Phe 0.40 +/− 0.02
M2
F5.47
Phe 0.25 +/− 0.02
F3Phe 0.31 +/− 0.02
Cha 0.97 +/− 0.04
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